Scalable throughput and flexibility for virtually any genome, sequencing method, and scale of project
All Kits & Reagents
Enable comprehensive genomic profiling with accurate and comprehensive homologous recombination deficiency assessment
All Selection & Planning Tools
Discover novel trait and disease associations with optimized tag SNPs and functional exonic content at an attractive price
All Software & Informatics
DRAGEN v4.0 release enables machine learning by default, providing increased accuracy out of the box
Fast, high-quality, sample-to-data services such as RNA and whole-genome sequencing
All Popular Products
Whole-exome sequencing kit with library prep, hybridization reagents, exome probe panel, size selection beads, and indexes
See what is possible through the latest advances in high-throughput sequencing technology
All Informatics Education
More About Us
Join us at the Illumina Genomics Forum in San Diego, September 28-October 1.
More Career Info
All Investor Information
More Business Solutions
All Legal Information
Get instructions for using Illumina DRAGEN Bio-IT Platform v4.0
All Support Tools
All Product Support Services
All Cancer Research Products
All Microbial Genomics Research
Monitor SARS-CoV-2 variants and other respiratory viruses in the community
All Microbial Genomics Products
All Informatics Products
Mapping genetic diversity to identify where confiscated gorillas come from and boost survival rates
All Agrigenomics Products
Explore the advantages of NGS for analysis of gene expression, gene regulation, and methylation
All Complex Disease Research Products
All Reproductive Health
Comprehensive, IVD, in-lab aneuploidy screening solution for accurate NIPT results in 26 hours
All Reproductive Health Products
Whole-genome sequencing (WGS) for rare disease offers key advantages over other genetic testing methods
All Genetic Health Products
Using a single test assessing hundreds of current and
emerging cancer biomarkers, you can now access a
clinically relevant report with actionable answers.
The MiSeqDx instrument is the first FDA-cleared <i>in vitro</i> diagnostic (IVD) next-generation sequencing (NGS) system.
MiSeqDx applications include FDA-cleared and FDA-approved assays for cystic fibrosis testing, colorectal cancer evaluation, and NGS-based assay development.
FDA-cleared next-generation sequencing panels for detection of causative and clinically relevant variants for cystic fibrosis.